IQVIA Holdings Inc. $IQV Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 30.3% in the 4th quarter, Holdings Channel reports. The fund owned 207,903 shares of the medical research company’s stock after selling 90,393 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in IQVIA were worth $46,864,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA in the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new position in IQVIA during the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. CrossGen Wealth LLC purchased a new stake in IQVIA in the 4th quarter valued at $28,000. Finally, Activest Wealth Management increased its stake in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on IQV shares. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $222.56.

IQVIA Stock Up 0.2%

Shares of IQV opened at $168.14 on Friday. The company’s 50-day moving average price is $173.63 and its 200 day moving average price is $191.68. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $28.06 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 1.44 and a beta of 1.21.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.